GERON CORP Financial and Nonfinancial Liabilities, Fair Value Disclosure
GERON CORP (GERN) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $129.63 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $129.63M.
- 2026-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $129.77M.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $129.58M.
- 2024-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $124.79M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $129.63M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $129.77M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $129.58M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $124.79M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |